N-[2-methoxy-5-(4-methyl-6-morpholin-4-ylpyrimidin-5-ylethynyl)-pyridin-3-yl]-benzenesulfonamide | 1391977-95-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[2-methoxy-5-(4-methyl-6-morpholin-4-ylpyrimidin-5-ylethynyl)-pyridin-3-yl]-benzenesulfonamide
• 英文别名: N-[2-methoxy-5-[2-(4-methyl-6-morpholin-4-ylpyrimidin-5-yl)ethynyl]pyridin-3-yl]benzenesulfonamide
• CAS: 1391977-95-9
• 化学式: C₂₃H₂₃N₅O₄S
• 分子量: 465.533
• InChiKey: LJBPIHRTGIOTFY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  115
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  5-溴-2-氯-3-硝基吡啶 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 吡啶 、 tin(II) chloride dihdyrate 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 N-[2-methoxy-5-(4-methyl-6-morpholin-4-ylpyrimidin-5-ylethynyl)-pyridin-3-yl]-benzenesulfonamide
  参考文献：
  名称：

  [EN] NEW 5-ALKYNYL-PYRIDINES
  [FR] NOUVELLES 5-ALKYNYL-PYRIDINES

  摘要：

  这项发明涉及一般式(I)的5-炔基吡啶，它们作为P13Kalpha活性抑制剂的用途，含有它们的药物组合物，以及它们作为治疗和/或预防由过度或异常细胞增殖和相关疾病条件（如癌症）所特征的疾病的药物的用途。R1到R6和n的含义如索赔和说明书中所述。

  公开号：

  WO2012101186A1

文献信息

• 5-Alkynyl-pyridines
  申请人：BOEHRINGER INGELHEIM INTERNATIONAL GMBH

  公开号：EP2546249A1

  公开（公告）日：2013-01-16

  This invention relates to 5-alkynyl-pyridine of general formula (I) their use as inhibitors of the activity ofPI3Kalpha, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The groups R1 to R6 and n have the meanings given in the claims and in the specification.

  这项发明涉及一般式(I)的5-炔基吡啶 它们作为PI3Kα活性抑制剂的用途，含有它们的药物组合物，以及它们作为治疗和/或预防由细胞过度或异常增殖引起的疾病及相关症状（如癌症）的药物的用途。 R1到R6和n的含义如权利要求和说明书中所述。
• 5-ALKYNYL-PYRIDINES
  申请人：WUNBERG Tobias

  公开号：US20130023519A1

  公开（公告）日：2013-01-24

  5-alkynyl-pyridine of general formula (I) their use as inhibitors of the activity of PI3Kalpha, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The groups R 1 to R 6 and n have the meanings given in the claims and in the specification.

  通式（I）的5-炔基吡啶，其作为PI3Kα活性抑制剂的用途，包含它们的制药组合物，以及它们作为治疗和/或预防由过度或异常细胞增殖所特征化的疾病及相关病症（如癌症）的药物的用途。其中，基团R1至R6和n的含义在权利要求和说明书中给出。
• NEW 5-ALKYNYL-PYRIDINES
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2668179A1

  公开（公告）日：2013-12-04
• EP2668179B1
  申请人：——

  公开号：EP2668179B1

  公开（公告）日：2017-08-16
• COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS
  申请人：BROWN Dennis M.

  公开号：US20160067241A1

  公开（公告）日：2016-03-10

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to naphthalimides such as amonafide or analogs, derivatives, or prodrugs thereof.